

ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. If necessary, this list will be updated with every issue of *PF*. This information will also be available as a cumulative table in future *Supplements* and will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement; call 1-800-822-USPC.

USP32–NF27 Page	Title	Section	Description
2409	Sodium Fluoride F18 Injection	Radiochemical Purity	Line 3 under <i>Chromatographic system</i> : Change “7.5-mm × 30-cm column that contains 10-μm packing L17.” to: 10-mm × 25-cm column that contains 10-μm packing L31.
3411	Propofol	Limit of propofol related compound A	Line 6 under <i>Procedure</i> : Change “0.01(r_U/r_S) in which r_U and r_S are the peak responses for propofol related compound A obtained from the <i>Test solution</i> and the <i>Standard solution</i> , respectively” to: $100(C_S/C_U)(r_U/r_S)$ in which C_S is the concentration, in mg per mL, of USP Propofol Related Compound A RS in the <i>Standard solution</i> ; C_U is the concentration, in mg per mL, of propofol in the <i>Test solution</i> ; and r_U and r_S are the peak responses for propofol related compound A obtained from the <i>Test solution</i> and the <i>Standard solution</i> , respectively
First Supplement to USP32–NF27			
4063	Haloperidol Decanoate	Assay	Footnote 11 under <i>Table 1</i> : Change “4-(4'-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.” to: 4-(3'-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. Footnote 12 under <i>Table 1</i> : Change “4-(3'-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.” to: 4-(4'-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
Second Supplement to USP32–NF27			
4152	(785) Osmolality and Osmolarity	Measurement of Osmolality	Line 2 under <i>Standard Solutions</i> : Change footnote “1” to: 2 At the bottom of page: Change footnote “1” to: 2

U S P 3 3 – NF28 Reissue Page	Title	CATEGORY Section	Description
R-140	Reagent Specifications	3,5-Dimethylphenol	Line 4: Change “from Lancaster Synthesis, Inc., www.lancastersynthesis.com” to: from www.alfa.com
R-142	Reagent Specifications	Ether, Peroxide-Free	Line 11: Change “www.jtbaker.com” to: www.mallbaker.com
R-203	Chromatographic Columns	L54	Line 4: Change “from Amersham Pharmacia Biotech (www.amershambiosciences.com)” to: from www.gelifesciences.com
R-316	Oil- and Water-Soluble Vitamins with Minerals Capsules	STRENGTH Vitamin A, Method 1	Line 14 under <i>Analysis</i> : Change “retinol acetate” to: retinyl acetate
R-453	Amiodarone Hydrochloride	SPECIFIC TESTS Limit of Iodides	Line 2 under <i>Standard solution</i> : Change “1.0 mL of an 88.2 mg/mL solution of potassium iodide” to: 1.0 mL of an 88.2 mg/L solution of potassium iodide

USP 33 – NF28 Reissue Page	Title	CATEGORY Section	Description
R-472	<i>Clarithromycin Tablets</i>	ASSAY Procedure	Line 1 under <i>Sample stock solution</i> : Change “Equivalent to 4 mg/mL of clarithromycin in methanol.” to: Equivalent to 4 mg/mL of clarithromycin from finely powdered Tablets in methanol.
R-510	<i>Mycophenolate Mofetil</i>	SPECIFIC TESTS Loss on Drying (731)	Line 1: Change “Dry a sample at 60° for 3 h: it loses NMT 0.5% of its weight.” to: Dry a sample in a vacuum at 60° for 3 h: it loses NMT 0.5% of its weight.
R-534	<i>Ritonavir</i>	IMPURITIES Organic Impurities, Procedure	In each row of <i>Impurity Table 1</i> under the column head <i>Relative Response Factor</i> with a value of “—”, change to: 1.0
R-534	<i>Ritonavir</i>	IMPURITIES Organic Impurities, Procedure	In each row of <i>Impurity Table 1</i> under the column head <i>Acceptance Criteria, NMT (%)</i> with a value of “—”, change to: 0.1
First Supplement to the USP33-NF28 Reissue			
R-645	(1024) <i>Bovine Serum</i>	Appendix 1	Line 3 under FDA, first bullet: Change “ http:// www.fda.gov/Cber/ltr/bse04l900.pdf ” to: Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105877.htm Line 4 under FDA, second bullet: Change “Available at http:// www.fda.gov/cber/rules/catruminant.pdf ” to: Available at: http://www.reginfo.gov/public/
R-984	<i>Ticlopidine Hydrochloride</i>	IMPURITIES Organic Impurities, Procedure 2	Footnote <i>a</i> under <i>Impurity Table 2</i> : Change “ <i>N</i> -(2-Chlorobenzyl)-2-(thiophen-2-yl)ethanamine.” to: 2-[<i>N</i> -Methyl- <i>N</i> -(2-chlorobenzyl)aminoethyl] thiophene hydrochloride.
Second Supplement to the USP33-NF28 Reissue			
R-1034	(11) <i>USP Reference Standards</i>	<i>USP Allopurinol Related Compound F RS</i>	Line 1: Change “[ethyl 3-(2-carbethoxy-” to: [ethyl (<i>E/Z</i>)-3-2(2-carbethoxy-
R-1041	(11) <i>USP Reference Standards</i>	<i>USP Doxepin Related Compound A RS</i>	Line 1: Change “[5-(4-nitrophenyl)-2-furaldehyde-2-carboxymethyl semicarbazone]” to: [dibenzo[<i>b,e</i>]oxepin-11(6 <i>H</i>)-one]
R-1063	(92) <i>Growth Factors and Cytokines Used in Cell Therapy Manufacturing</i>	SPECIFIC TESTS Bioidentity	Line 1 under <i>Resazurin solution</i> : Change “0.11 mg of resazurin in <i>Phosphate buffered saline</i> .” to: 11 mg of resazurin in 100 mL of <i>Phosphate buffered saline</i> .